Sarepta Therapeutics Stock News

We have narrowed our search to five mid-caps that have strong potential for 2024. These are: DVA, MNDY, GTLB, LNW, SRPT.

Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near

Sarepta (SRPT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise.

Sarepta Therapeutics (NASDAQ: SRPT ) stock is rising higher on Tuesday after positive comments were made by its CEO at the JPMorgan Healthcare Conference. Sarepta Therapeutics CEO Douglas Ingram said

Sarepta Therapeutics boasts excellent innovative abilities and a deep pipeline. DexCom still has a huge growth runway left in the continuous glucose monitoring market.

REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.

Dyne Therapeutics Inc. shares DYN, -1.80% jumped 40% premarket on Wednesday after the company released new data from trials of two investigational treatments for genetic muscle disorders. The experime

GWRS, SRPT, AVTX, NTGR and PAY have been added to the Zacks Rank #1 (Strong Buy) List on January 3, 2024.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 42nd

Sarepta (SRPT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Sarepta Therapeutics recently launched a new medicine. It already has several on the market, but the company isn't yet profitable.

Sarepta (SRPT) files a supplement with the FDA seeking to expand its recently-approved gene therapy Elevidys' label to treat all DMD patients, regardless of age and ambulatory status.

Sarepta Therapeutics and Vertex Pharmaceuticals already have a lot in common. Sarepta's focus market has a few peculiarities that could pose a problem.

Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provid

Sarepta has encountered several issues related to its gene therapy for Duchenne muscular dystrophy. The small biotech is still generating solid financial results and has an extensive pipeline of progr